Abhinav Shukla, serving as the Chief Technical Officer for Shattuck Labs, Inc. (NASDAQ:STTK), has completed the sale of company shares amounting to roughly $166,131. The liquidation occurred across two distinct dates, June 30 and July 1, 2026, following the exercise of stock options. These movements take place against a backdrop of significant price appreciation for STTK, which is currently trading at $7.05. This price point represents an extraordinary 746% gain over the last twelve months. However, independent analysis indicates that the stock's current valuation may exceed its fair value, placing it within the category of companies considered overvalued.
On June 30, 2026, Shukla sold 23,365 shares of common stock. The weighted average price for this block was $7.08 per share, with individual transactions occurring at prices ranging between $7.00 and $7.41. The following day, July 1, 2026, he sold an additional 100 shares at $7.07 per share. The aggregate value of these sales reached approximately $166,131, with transaction prices clustering tightly between $7.07 and $7.08. Both sets of sales were executed under a Rule 10b5-1 trading plan adopted on February 2, 2026. This plan was designed specifically to fund the exercise price and estimated tax withholding associated with the option exercises.
Prior to selling, Shukla acquired the corresponding shares through option exercises. On June 30, 2026, he acquired 23,365 shares at an exercise price of $3.57 per share. On July 1, 2026, he acquired another 100 shares at the same exercise price. The total value of these acquisitions was approximately $83,770. These options grant the right to purchase common stock, with a portion vesting on January 25, 2024, and the remainder vesting in equal monthly installments through January 25, 2027, contingent upon Shukla's continued service to the company.
Following these transactions, Shukla's direct ownership of Shattuck Labs common stock stands at 86,380 shares. He also holds 26,703 stock options, representing the right to buy additional shares. Shattuck Labs, a biotech firm, currently maintains a market capitalization of $534 million and reports a strong liquidity position with a current ratio of 22.06. The company is also engaged in a public offering aimed at raising approximately $75 million in gross proceeds. This offering includes 10,879,376 shares of common stock priced at $4.00 per share and pre-funded warrants for an additional 7,870,624 shares. Shattuck Labs expects to receive $54.9 million from the exercise of approximately 50.6 million common stock warrants, representing about 96% of the warrants issued in a previous private placement. These funds are intended to support ongoing operations and development efforts.
In clinical developments, Shattuck Labs reported positive Phase 1 trial results for SL-325, its DR3 blocking antibody candidate. The trial involved 72 healthy volunteers across various dose cohorts and revealed a low immunogenicity profile, with only 3.7% of participants developing antidrug antibodies. The company has also provided underwriters with a 30-day option to purchase up to an additional 15% of shares at the public offering price.